PRECISION SPINAL CORD STIMULATION(SCS) SYSTEM
Boston Scientific Corp · Decision date Apr 27, 2004
What did the FDA approve?
The FDA database entry records an original PMA approval, dated April 27, 2004, for the Precision Spinal Cord Stimulation (SCS) System from Boston Scientific Corp. The decision field states approval for the device as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
The entry contains no supplement type or supplement reason, so this is not a change to a previously approved system. The statement reports the device's indicated purpose as written in the approval record; it does not by itself provide independent evidence of safety or clinical effectiveness. No additional technical specifications, trial data, or labeling details beyond the quoted indication are present in the source fields.
FDA approval order statement
APPROVAL FOR THE PRECISION SPINAL CORD STIMULATION (SCS) SYSTEM. THE DEVICE IS INDICATED AS AN AID IN THE MANAGEMENT OF CHRONIC INTRACTABLE PAIN OF THE TRUNK AND/OR LIMBS, INCLUDING UNILATERAL OR BILATERAL PAIN ASSOCIATED WITH THE FOLLOWING: FAILED BACK SURGERY SYNDROME, INTRACTABLE LOW BACK PAIN AND LEG PAIN.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Apr 27, 2004
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030017
- Regulatory pathway
- Premarket approval application
- Applicant
- Boston Scientific Corp
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Apr 27, 2004
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Boston Scientific Corp
- Product code
- LGW
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P030017 received
Application receipt date recorded by FDA.
P030017 · FDA decision
APPR
P030017/S386 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S389 · Related supplement
WaveWriter Alpha Prime Spinal Cord Stimulation (SCS) Systems
P030017/S390 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S374 · Related supplement
WaveWriter Alpha Spinal Cord Stimulator (SCS) Mixed Systems, M8 Adaptor
P030017/S377 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S391 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S387 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems Introducer Hub Mold Change
P030017/S394 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S395 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S392 · Related supplement
Celestia Implantable Pulse Generator, Celestia External Trial Stimulator
P030017/S393 · Related supplement
Spinal Cord Stimulation (SCS)
P030017/S397 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S398 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S396 · Related supplement
WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems
P030017/S399 · Related supplement
Precision Spectra SCS Systems; Precision Novi SCS Systems; Precision Montage MRI SCS Systems; Spectra Wave Writer SCS Sy
Timeline entries are records held by MedtechLedger for P030017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030017
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P030017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






